CER Daily Newsfeed

Comparative Study: Asthma Treatments in English Practices

(9/25, Bioengineer.org) reports “...In conclusion, the real-world comparative effectiveness study investigating FF/VI versus BDP/F in asthma management highlights critical insights for clinicians, patients, and healthcare systems. By leveraging real-world data, the researchers not only shed light on treatment effectiveness but also contributed significantly to the discourse on personalized medicine in asthma care. Future studies will be essential to build on these findings and further define optimal treatment pathways, ensuring that patient-centered care remains at the forefront of asthma management.” Full

What to Know about AHEAD, CMS’ Revamped All-Payer Model

(9/25, Bridget Early, Medscape) reports “...Accountable for Health CEO Mara McDermott said AHEAD can be a means to unravel a longstanding conundrum: How do providers and ACOs connect with people who don’t interact with the healthcare system? Rhode Island Health Insurance Commissioner Cory King said AHEAD could play a critical role in the state’s efforts to reduce costs. But King acknowledged the model’s complexity, and said recruiting providers may pose a challenge...Primary Care Collaborative CEO Ann Greiner said AHEAD could help align financial incentives between hospitals and primary care providers, thereby addressing patient needs sooner and preventing hospitalizations.” Subscription Required

Privia Health buys Evolent Health's ACO business for $100M

(9/25, Heather Landi, Fierce Healthcare) reports “...Through the deal, Privia Health will add Evolent Care Partners' more than 120,000 attributed lives in the Medicare Shared Savings Program (MSSP) as well as various commercial and Medicare Advantage programs. With the deal, Privia Health will now serve approximately 1.5 million attributed lives in VBC arrangements across commercial, Medicare, Medicare Advantage and Medicaid.” Full

Overcoming Barriers to Oncology Combination Therapies in the UK and EU

(9/25, Anastasia Stamoulou, Dr. Jennifer Gaultney, Saskia van Dijk, Drug Target Review) reports “...Significant EU HTA regulation changes in 2025 designed to improve access to innovative health technologies for EU patients will likely necessitate more multi-country RWE studies. Joint clinical assessments (JCAs) began in January 2025 for oncology drugs with new active substances and advanced therapy medicinal products. JCAs aim to centralise and standardise the HTA process to streamline approvals across the EU.” Full

Europe Promotes Real-World Data to Improve Drug Regulation

(9/25, Silvia C. Carpallo, Medscape) reports “...According to the DARWIN EU, by 2025, data from 181,128,000 patients across Europe will contribute to approximately 100 studies per year involving approximately 40 partners. Working with the EMA and its Scientific Technical Committee, the coordination centre continues to expand the network by adding new partners and data sources while integrating advanced infrastructure and techniques.” Full

Greece Aligns with EU on Health Technology Assessment

(9/24, Tovima.com) reports “...‘This is the first step toward a full legislative redesign to ensure complete alignment with the European regulation,’ said Aris Angelis, Secretary General for Strategic Planning at the Health Ministry. He noted that a pilot application will begin with one pharmaceutical product, followed by gradual improvements, stressing that the reform ‘responds to real system needs and, above all, to the needs of patients.’” Full

Patient-Centered Access to New Drugs Is the Core of Future Healthcare: KRPIA

(9/25, Kim Yun-mi, Korea Biomedical Review) reports “To address the issue of ‘low access to new drugs’ facing Korea, the pharmaceutical and biotech industry, patient groups, academia, and the government gathered together. At a forum held on Wednesday to mark the 25th anniversary of the Korea Research-based Pharma Industry Association (KRPIA), participants reaffirmed that designing patient-centered policies is an urgent task that can no longer be delayed.” Full